Literature DB >> 8158033

Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up.

A D Klion1, E A Ottesen, T B Nutman.   

Abstract

Although successful treatment of loiasis with diethylcarbamazine (DEC) has been reported, little is known about the long-term success rate of therapy or the predisposing factors for treatment failure. To address these questions, 32 patients were followed 2-15 years (median, 4.5) after DEC treatment; all had acquired infection while expatriate visitors to endemic areas of Africa. Using a strict definition of successful treatment, 12 (38%) appeared to be cured after one course of therapy and 5(16%) after two courses. Of the remaining 15 patients, 3 continued to be symptomatic despite more than four courses of treatment. Although 12 of the 17 patients who relapsed did so within 1 year of treatment, several had relatively long asymptomatic periods (2-8 years). There was no predictive difference in clinical or laboratory parameters (including eosinophilia and specific filarial serology) between patients requiring one or more courses of therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158033     DOI: 10.1093/infdis/169.3.604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.

Authors:  Delynn M Moss; Jeffrey W Priest; Alexis Boyd; Tiffany Weinkopff; Zuzana Kucerova; Michael J Beach; Patrick J Lammie
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

2.  Clinical Features of Imported Loiasis: A Case Series from the Hospital for Tropical Diseases, London.

Authors:  Makoto Saito; Margaret Armstrong; Samuel Boadi; Patricia Lowe; Peter L Chiodini; Tom Doherty
Journal:  Am J Trop Med Hyg       Date:  2015-06-22       Impact factor: 2.345

3.  Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa.

Authors:  Jesica A Herrick; Michelle A Makiya; Nicole Holland-Thomas; Amy D Klion; Thomas B Nutman
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

4.  A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.

Authors:  Fanny Legrand; Jesica Herrick; Michelle Makiya; Roshan Ramanathan; Reagan Thompson; Shakuntala Rampertaap; Jennifer Stoddard; JeanAnne Ware; Michael P Fay; Nicole Holland-Thomas; Thomas B Nutman; Amy D Klion
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

5.  [Bilateral subconjunctival foreign bodies. Loiasis with bilateral Loa ophthalmia].

Authors:  J Stammen; M Klüppel
Journal:  Ophthalmologe       Date:  2002-04       Impact factor: 1.059

6.  Filarial infections in travelers and immigrants.

Authors:  Amy D Klion
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

7.  [Ocular involvement in systemic Loa-Loa filariasis. Case report and review of the literature].

Authors:  A Jaksche; L Wessels; S Martin; K U Loeffler
Journal:  Ophthalmologe       Date:  2004-09       Impact factor: 1.059

Review 8.  [Parasitic dermatoses from abroad].

Authors:  Robert Rongisch; Luisa Bopp; Mario Fabri; Esther von Stebut
Journal:  Hautarzt       Date:  2021-02       Impact factor: 0.751

9.  Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial.

Authors:  Joseph Kamgno; Patrick Nguipdop-Djomo; Raceline Gounoue; Mathurin Téjiokem; Annette C Kuesel
Journal:  PLoS Negl Trop Dis       Date:  2016-03-11

10.  Genome Filtering for New DNA Biomarkers of Loa loa Infection Suitable for Loop-Mediated Isothermal Amplification.

Authors:  Catherine B Poole; Laurence Ettwiller; Nathan A Tanner; Thomas C Evans; Samuel Wanji; Clotilde K S Carlow
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.